• Rigel Pharmaceuticals, a biotechnology company focused on hematologic disorders and cancer, announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Cantor Global Healthcare Conference on Thursday, September 19, 2024.
• The presentation will take place in New York, NY.
• Rigel Pharmaceuticals is a biotechnology company focused on hematologic disorders and cancer.
• Rodriguez will be the keynote speaker at the conference.
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Cantor Global Healthcare Conference on Thursday, September 19, at 9:10 am ET in New York, NY.
To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.
Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
David Rosen
Argot Partners
212.600.1902
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$13.63 |
| Daily Change: | -0.05 -0.37 |
| Daily Volume: | 61,372 |
| Market Cap: | US$239.890M |
September 05, 2024 September 03, 2024 August 06, 2024 June 24, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
